Towards the preparative and large-scale precision manufacture of virus-like particles

Pattenden, Leonard Keith; Middelberg, Anton P. J.; Niebert, Marcus; Lipin, Daniel I.

doi:10.1016/j.tibtech.2005.07.011

Cited by 164 publications

(123 citation statements)

References 51 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…50,51 Recently, VNPs (viruses as nanocontainers) have been widely explored for nanotechnological purposes, including drug delivery, gene therapy, vaccination, imaging and targeting. 52 50,51,53 As an arising nanocarrier platform, VNPs offer several attractive features including morphological uniformity, biocompatibility, easy surface functionalization and availability in a variety of sizes and shapes. 53 Possibility of versatile chemical and genetic modifications on their surface enables VNPs to meet the requirements of drug nanocarriers including biocompatibility, hydrophilicity and enhanced drug entrapment proficiency.…”

Section: Virus-based Nanoparticles (Vnps)mentioning

confidence: 99%

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Din

Aman

Ullah³

et al. 2017

IJN

1,160

481

View full text Add to dashboard Cite

Nanotechnology has recently gained increased attention for its capability to effectively diagnose and treat various tumors. Nanocarriers have been used to circumvent the problems associated with conventional antitumor drug delivery systems, including their nonspecificity, severe side effects, burst release and damaging the normal cells. Nanocarriers improve the bioavailability and therapeutic efficiency of antitumor drugs, while providing preferential accumulation at the target site. A number of nanocarriers have been developed; however, only a few of them are clinically approved for the delivery of antitumor drugs for their intended actions at the targeted sites. The present review is divided into three main parts: first part presents introduction of various nanocarriers and their relevance in the delivery of anticancer drugs, second part encompasses targeting mechanisms and surface functionalization on nanocarriers and third part covers the description of selected tumors, including breast, lungs, colorectal and pancreatic tumors, and applications of relative nanocarriers in these tumors. This review increases the understanding of tumor treatment with the promising use of nanotechnology.

show abstract

Section: Virus-based Nanoparticles (Vnps)mentioning

confidence: 99%

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Din

Aman

Ullah³

et al. 2017

IJN

1,160

481

View full text Add to dashboard Cite

show abstract

“…The use of purification methods that do not sharply discriminate between the recombinant products and BV particles might result in contamination of the sample with BV virions. This may be the case for crude purification methods based on size discrimination, such as gradient centrifugation, microfiltration (0.45 m), and ultrafiltration (300 kDa)-routine protocols for the downstream processing of different BV-derived virus-like particles (VLPs) in preclinical studies (6,7). To obtain authorisation for commercial use, a recombinant protein must fulfil a series of safety and regulatory requirements.…”

mentioning

confidence: 99%

Insect Baculoviruses Strongly Potentiate Adaptive Immune Responses by Inducing Type I IFN

Hervás-Stubbs

Rueda

López

et al. 2007

The Journal of Immunology

155

View full text Add to dashboard Cite

Baculoviruses (BVs) are dsDNA viruses that are pathogenic for insects. They have been used worldwide as selective bioinsecticides and for producing recombinant proteins in insect cells. Surprisingly, despite their widespread use in research and industry and their dissemination in the environment, the potential effects of these insect viruses on the immune responses of mammals remain totally unknown. We show in this study that BVs have strong adjuvant properties in mice, promoting potent humoral and CD8+ T cell adaptive responses against coadministered Ag. BVs also induce the in vivo maturation of dendritic cells and the production of inflammatory cytokines. We demonstrate that BVs play a major role in the strong immunogenicity of virus-like particles produced in the BV-insect cell expression system. The presence of even small numbers of BVs among the recombinant proteins produced in the BV expression system may therefore strengthen the immunological properties of these proteins. This adjuvant behavior of BVs is mediated primarily by IFN-αβ, although mechanisms independent of type I IFN signaling are also involved. This study demonstrates that nonpathogenic insect viruses may have a strong effect on the mammalian immune system.

show abstract

“…[40,43]. In addition, virus-like particles (VLP) are suitable for CV design since this delivery technology is reliable [45][46][47] and currently used in the newly FDA-approved HPV vaccine [48,49].…”

Section: Viral and Dna Vectorsmentioning

confidence: 99%

Combination vaccines: design strategies and future trends

Igietseme¹,

Eko²,

He³

et al. 2006

Expert Review of Vaccines

View full text Add to dashboard Cite

Towards the preparative and large-scale precision manufacture of virus-like particles

Cited by 164 publications

References 51 publications

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Insect Baculoviruses Strongly Potentiate Adaptive Immune Responses by Inducing Type I IFN

Combination vaccines: design strategies and future trends

Contact Info

Product

Resources

About